Losartan slows pancreatic tumor progression and extends survival of SPARC-null mice by abrogating aberrant TGFβ activation.

Arnold SA, Rivera LB, Carbon JG, Toombs JE, Chang CL, Bradshaw AD, Brekken RA
PLoS One. 2012 7 (2): e31384

PMID: 22348081 · PMCID: PMC3279359 · DOI:10.1371/journal.pone.0031384

MeSH Terms (14)

Angiotensin II Type 1 Receptor Blockers Animals Disease Progression Extracellular Matrix Losartan Mice Mice, Knockout Neoplasm Invasiveness Neoplasm Metastasis Osteonectin Pancreatic Neoplasms Survival Rate Transforming Growth Factor beta Treatment Outcome

Connections (1)

This publication is referenced by other Labnodes entities:

Links